IL13RA2 and breast carcinoma: Consistent with our findings, increased immunohistochemical IL-13Rα2 expression was significantly associated with poorer survival outcomes in patients with gastric carcinoma [38], renal cell carcinoma [16], colorectal cancers [14], and luminal-type breast carcinomas [39].